同大類學(xué)科其它級別期刊:
中科院 1區(qū) 期刊 JCR Q1 期刊 中科院 2區(qū) 期刊 JCR Q2 期刊 中科院 3區(qū) 期刊 JCR Q3 期刊 中科院 4區(qū) 期刊 JCR Q4 期刊國際簡稱:MINERVA UROL NEPHROL 參考譯名:Minerva 泌尿科和腎臟科
主要研究方向:UROLOGY & NEPHROLOGY 非預(yù)警期刊 審稿周期:
《Minerva 泌尿科和腎臟科》(Minerva Urology And Nephrology)是一本由Edizioni Minerva Medica出版的以UROLOGY & NEPHROLOGY為研究特色的國際期刊,發(fā)表該領(lǐng)域相關(guān)的原創(chuàng)研究文章、評論文章和綜述文章,及時(shí)報(bào)道該領(lǐng)域相關(guān)理論、實(shí)踐和應(yīng)用學(xué)科的最新發(fā)現(xiàn),旨在促進(jìn)該學(xué)科領(lǐng)域科學(xué)信息的快速交流。該期刊是一本未開放期刊,近三年沒有被列入預(yù)警名單。該期刊享有很高的科學(xué)聲譽(yù),影響因子不斷增加,發(fā)行量也同樣高。
Minerva Urology And Nephrology is an academic journal dedicated to the fields of urology and nephrology, covering a wide range of topics from basic research to clinical practice. This journal provides a communication platform for urologists and nephrologists to share the latest research findings, treatment methods, and clinical cases.
In the field of urology, the journal discussed the diagnosis, treatment and prevention strategies of urinary system tumors, including prostate cancer, bladder cancer, kidney cancer, etc. At the same time, it also includes in-depth analysis of common diseases such as benign prostatic hyperplasia, urinary stones, and urinary incontinence. These studies not only help improve doctors' understanding of diseases, but also provide patients with more treatment options. Nephrology focuses on the pathological mechanism, clinical manifestations and treatment methods of various kidney diseases, such as chronic kidney disease, acute kidney injury, diabetes nephropathy, etc. In addition, the latest developments in renal replacement therapy such as hemodialysis, peritoneal dialysis, and kidney transplantation were also discussed. These contents are of great significance for improving the quality of life and prolonging the survival period of kidney disease patients.
CiteScore | SJR | SNIP | CiteScore 指數(shù) | ||||||||||||
8.5 | 1.102 | 1.201 |
|
名詞解釋:CiteScore 是衡量期刊所發(fā)表文獻(xiàn)的平均受引用次數(shù),是在 Scopus 中衡量期刊影響力的另一個(gè)指標(biāo)。當(dāng)年CiteScore 的計(jì)算依據(jù)是期刊最近4年(含計(jì)算年度)的被引次數(shù)除以該期刊近四年發(fā)表的文獻(xiàn)數(shù)。例如,2022年的 CiteScore 計(jì)算方法為:2022年的 CiteScore =2019-2022年收到的對2019-2022年發(fā)表的文件的引用數(shù)量÷2019-2022年發(fā)布的文獻(xiàn)數(shù)量 注:文獻(xiàn)類型包括:文章、評論、會議論文、書籍章節(jié)和數(shù)據(jù)論文。
Top期刊 | 綜述期刊 | 大類學(xué)科 | 小類學(xué)科 | ||
否 | 否 | 醫(yī)學(xué) | 2區(qū) | UROLOGY & NEPHROLOGY 泌尿?qū)W與腎臟學(xué) | 2區(qū) |
Top期刊 | 綜述期刊 | 大類學(xué)科 | 小類學(xué)科 | ||
否 | 否 | 醫(yī)學(xué) | 2區(qū) | UROLOGY & NEPHROLOGY 泌尿?qū)W與腎臟學(xué) | 2區(qū) |
按JIF指標(biāo)學(xué)科分區(qū) | 收錄子集 | 分區(qū) | 排名 | 百分位 |
學(xué)科:UROLOGY & NEPHROLOGY | SCIE | Q1 | 13 / 126 |
90.1% |
按JCI指標(biāo)學(xué)科分區(qū) | 收錄子集 | 分區(qū) | 排名 | 百分位 |
學(xué)科:UROLOGY & NEPHROLOGY | SCIE | Q1 | 14 / 126 |
89.29% |
Frontiers In Public Health
中科院 3區(qū) JCR Q2
Frontiers In Pharmacology
中科院 2區(qū) JCR Q1
Biomedicine & Pharmacotherapy
中科院 2區(qū) JCR Q1
Discover Oncology
中科院 4區(qū) JCR Q2
Bmc Psychiatry
中科院 2區(qū) JCR Q2
Bmc Neurology
中科院 3區(qū) JCR Q3
Journal Of Materials Chemistry B
中科院 3區(qū) JCR Q1
Medcomm
中科院 3區(qū) JCR Q1